Locations
Cambridge, MA, USA · North America · Cambridge, MA, USA
industry
Biotechnology
Size
51-200 employees
Stage
Series C+
founded in
2015
Egenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues, and cells. Harnessing the latest gene-editing techniques, Egenesis’ mission is to solve the global organ shortage crisis by developing a scalable alternative to allotransplantation. Egenesis is reinvigorating the field of xenotransplantation by addressing the key virology and immunology hurdles that have prevented its advancement to date, and is developing commercially viable products to save and improve the lives of patients who are waiting for an organ transplant.
Something looks off?On-site & Remote